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(TTP) and progression-free survival (PFS) and OS in randomized
controlled trials (RCTs) for MBC. METHODS: A literature
search was conducted to retrieve all RCTs since 1994 in patients
with MBC (ﬁrst line and refractory) in which both progression
endpoints and OS were reported. Summary data, trial and
patient characteristics were abstracted and data analyzed using
Spearman correlation coefﬁcients and simple regression equa-
tions, similar to the approach used by Louvet et al. (Cancer
2001) for colorectal cancer. RESULTS: Of 582 study citations
retrieved, 68 met all eligibility criteria, including a total of
∼19,000 patients. Among 51 studies, reported TTP across treat-
ment groups averaged 6.9 months and OS averaged 20.5
months. Correlation between measures was 0.33 (p = 0.0007).
An additional 17 studies provided PFS (mean = 7.3 months).
However, deﬁnitions provided for TTP and PFS were not con-
sistent across studies and often overlapped. When all studies
were included and OS was compared to TTP or PFS, correlation
was 0.31 (p = 0.0002). Linear regression coefﬁcients suggest that
a 1-month increase in TTP or PFS corresponds to a commensu-
rate increase in OS (slope = 0.9). CONCLUSION: These results
suggest that increases in time to progression endpoints (TTP/PFS)
observed in MBC trials ultimately correspond to survival bene-
ﬁts as previously established in other tumor types. This ﬁnding
is particularly important since survival data from RCTs is often
obscured by subsequent treatments or patient cross-over.
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OBJECTIVES: To assess the ﬁnancial consequences of the intro-
duction of trastuzumab as adjuvant therapy for HER2-positive
early breast cancer (EBC) patients in Poland. METHODS: The
analysis was perfomed using modelling technique, based on
Polish epidemiologic data and cost estimates. Only direct
medical costs were included and assessed from health care payer
perspective. The baseline risk of disease progression and the
impact of trastuzumab on disease progression were taken from
HERA study. After determining the number of patients on
therapy expected over the 2007–2009 time horizon, the model
determines the cost of therapy in a scenario where trastuzumab
is not available in Poland (A) and a scenario where trastuzumab
is available (B). The model then calculates the trastuzumab-
related budget impact as the incremental costs associated with
The rapy in the population between the two scenarios consid-
ered above. Extreme scenario sensitivity analyses were per-
formed. RESULTS: According to epidemiologic data the
expected number of patients eligible for trastuzumab adjuvant
therapy would be 932 for each year between 2007–2009. Results
of the budget impact analysis suggest that expenditures are
expected to evolve with the introduction of trastuzumab in
Poland, from 60,057,901 PLN in 2007 to 119,415,721 PLN in
2008 and 117,662,121 in 2009, and between 2007–2009 would
increase by 297,135,743 PLN in total. Such an increase in cost
would be associated with acquisition and administration cost of
trastuzumab and would be only partially compensated by lower
costs of metastatic and recurrence health states in scenario B.
Sensitivity analysis shows that in all scenarios introduction of
trastuzumab as adjuvant therapy for HER2-positive EBC
patients requires the additional budget assessed at 253,772,456
PLN-302,924,889 PLN for the period 2007–2009. CONCLU-
SION: The increase in costs associated with the introduction of
trastuzumab as adjuvant therapy needs to be considered along-
side with improved clinical effectiveness for patients treated with
trastuzumab.
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OBJECTIVES: To evaluate the pharmacoeconomics, including
cost-effectiveness and budget impact, of the addition of 2 novel
treatments for MRCC in the Formulary of a large teaching
cancer center. METHODS: Prior to the FDA’s approval of
sorafenib and sunitinib, a majority of patients with MRCC
treated at our center received the BGC regimen. Sorafenib and
sunitinib were FDA-approved for MRCC in December 2005 and
January 2006 respectively. We created a pharmacoeconomic
model to characterize the expected use of sorafenib and sunitinib
compared to the traditional BGC therapy. The model was created
assuming equal use of both new agents (40%) and modest use
of the BGC regimen (20%). The time-to-progression (TTP) used
to calculate cost-effectiveness was based on clinical experience
at our institution (expert opinion) and clinical trials. The model
also accounts for the development of adverse events requiring
dose reductions based on our experience. Other parameters used
were average wholesale price (AWP), BSA = 2 m2, and average
weight = 70 kilograms. RESULTS: Approximately 144 patients
per year with MRCC receive treatment at our institution. The
institutional cost-effectiveness of these regimens is as follows:
sorafenib = $54,000/PFS-year; sunitinib = $59,000/PFS-year, and
BGC = $152,000/PFS-year. The overall budget impact of the
introduction of these 2 agents was a decrease in $3 million per
year in total drug costs to treat MRCC when compared to the
BCG regimen. CONCLUSION: Sorafenib and sunitinib offer
alternative treatment for MRCC and are associated with better
outcomes (longer TTP) and convenience (oral therapy). This was
important for our institution because bevacizumab, the most
costly agent in the BGC regimen, has not received FDA approval
for the treatment of MRCC and therefore, reimbursement for
this indication is limited. Sorafenib and sunitinib offer a supe-
rior treatment option at a lower cost and potential for improved
revenue.
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OBJECTIVES: In Mexico, breast cancer is the most common
tumour in women and by 2010 local estimations forecast that
more than 200 thousand Mexican women would need attention
due to this disease. The purpose of this study was to evaluate the
